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Objective. Tissue glucocorticoid (GC) levels are
regulated by the GC-activating enzyme 11-
hydroxysteroid dehydrogenase type 1 (11-HSD1). This
enzyme is expressed in cells and tissues arising from
mesenchymal stromal cells. Proinflammatory cytokines
dramatically increase expression of 11-HSD1 in stro-
mal cells, an effect that has been implicated in inflam-
matory arthritis, osteoporosis, obesity, and myopathy.
Additionally, GCs act synergistically with proinflamma-
tory cytokines to further increase enzyme expression.
The present study was undertaken to investigate the
mechanisms underlying this regulation.
Methods. Gene reporter analysis, rapid amplifi-
cation of complementary DNA ends (RACE), chemical
inhibition experiments, and genetic disruption of intra-
cellular signaling pathways in mouse embryonic fibro-
blasts (MEFs) were used to define the molecular mech-
anisms underlying the regulation of 11-HSD1
expression.
Results. Gene reporter, RACE, and chemical in-
hibitor studies demonstrated that the increase in 11-
HSD1 expression with tumor necrosis factor  (TNF)/
interleukin-1 (IL-1) occurred via the proximal
HSD11B1 gene promoter and depended on NF-B sig-
naling. These findings were confirmed using MEFs with
targeted disruption of NF-B signaling, in which RelA
(p65) deletion prevented TNF/IL-1 induction of 11-
HSD1. GC treatment did not prevent TNF-induced
NF-B nuclear translocation. The synergistic enhance-
ment of TNF-induced 11-HSD1 expression with GCs
was reproduced by specific inhibitors of p38 MAPK.
Inhibitor and gene deletion studies indicated that the
effects of GCs on p38 MAPK activity occurred primarily
through induction of dual-specificity phosphatase 1
expression.
Conclusion. The mechanism by which stromal cell
expression of 11-HSD1 is regulated is novel and
distinct from that in other tissues. These findings open
new opportunities for development of therapeutic inter-
ventions aimed at inhibiting or stimulating local GC
levels in cells of mesenchymal stromal lineage during
inflammation.
An increase in tissue levels of glucocorticoids
(GCs) is an important component of the inflammatory
response (1). Impairment of these counterregulatory
responses (e.g., by impaired GC synthesis or GC recep-
tor blockage) is associated with high mortality in inflam-
matory states in humans and animals (2,3). The antiin-
flammatory actions of GCs are mediated through
inhibition of proinflammatory signaling pathways such
as NF-B, activator protein 1 (AP-1), and MAPKs.
At the tissue level, the action of GCs is regulated
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by activity of the enzyme 11-hydroxysteroid dehydro-
genase type 1 (11-HSD1) (4,5), which interconverts
inactive GCs such as cortisone and dehydrocorticoster-
one with their active counterparts cortisol and cortico-
sterone. Expression of 11-HSD1 appears to be a com-
mon feature in all cell types that have a mesodermal
origin (6). Although 11-HSD1 activity can be bidirec-
tional, in these cells the activity is primarily in the
reductase direction (converting inactive GCs to their
active form). In osteoblasts, synovial fibroblasts, adi-
pocytes, and myocytes, 11-HSD1 expression, and con-
sequent GC activation, has been postulated to play a
role in the development of inflammation-associated
osteoporosis, arthritis, obesity, and myopathy, respec-
tively (7–11). We have previously reported that proin-
flammatory cytokines such as tumor necrosis factor 
(TNF) and interleukin-1 (IL-1) increase the expres-
sion and activity of 11-HSD1 in these mesenchymal
stromal cell types and tissues (7,10,12,13). In contrast,
proinflammatory cytokines have no effect on 11-HSD1
expression in hepatocytes, monocytes, or lymphocytes
(10,14,15). Furthermore, combined treatment with GCs
and proinflammatory cytokines synergistically increases
expression and activity of 11-HSD1 in osteoblasts,
synovial fibroblasts, and myocytes (13).
This ability of GCs to further stimulate, rather
than inhibit, inflammation-associated 11-HSD1 expres-
sion in mesenchymal stromal cells may be a feedforward
mechanism to selectively increase local GC action in
these cells during inflammation (16). The molecular
mechanisms involved in regulating expression of 11-
HSD1 in cells such as hepatocytes, monocytes, and
lymphocytes have been explored previously (14,15,17).
The best-characterized of these mechanisms is the in-
crease in 11-HSD1 expression in hepatocytes in re-
sponse to GCs; this is mediated by members of the
CCAAT/enhancer binding protein family and requires
new protein synthesis (17). However, to date none of
these studies have characterized signaling systems in-
volved in mediating the effects of proinflammatory
cytokines and GCs in mesenchymal stromal cells. This
raises the possibility that novel regulatory pathways
regulate these effects. Furthermore, the presence of
distinct regulatory mechanisms in musculoskeletal cells
might enable tissue-specific regulation of 11-HSD1
activity. In this study we examined the mechanisms
underlying the regulation of 11-HSD1 expression and
activity in osteoblasts, synovial fibroblasts, and myo-
blasts.
MATERIALS AND METHODS
Cell and tissue culture. Reagents were obtained from
Sigma unless noted otherwise. Primary synovial fibroblasts
were generated from synovial tissue obtained at the time of
knee arthroplasty from patients with rheumatoid arthritis
(RA) according to the American College of Rheumatology
1987 classification criteria (18) or with osteoarthritis (OA), as
previously described (12). Additionally, synovial fibroblasts
were generated from normal synovial tissue isolated from
subjects undergoing knee arthroscopy for noninflammatory
conditions. Isolated fibroblasts were grown in RPMI 1640
medium containing 1% (volume/volume) nonessential amino
acids, 1% penicillin/streptomycin, 1% sodium pyruvate, 2 mM
glutamine, and 20% fetal bovine serum (FBS; Labtech).
MG-63 osteosarcoma cells were cultured in modified Eagle’s
medium (MEM) with 10% FBS, 1% nonessential amino acids,
and 2 mmoles/liter L-glutamine. Human primary dermal fibro-
blasts were isolated from human skin by explant culture using
the same medium used for primary synovial fibroblasts (9).
C2C12 myocytes (European Collection of Cell Cultures) were
cultured in high-glucose Dulbecco’s MEM (DMEM) with 10%
FBS, 1% L-glutamine, and 4.5 gm/liter glucose (PAA). When
cells had reached 80% confluence, differentiation of myo-
cytes was initiated by replacing existing medium with high-
glucose DMEM (5% horse serum, 1% L-glutamine, 4.5 gm/
liter glucose). Primary human hepatocytes from a 57-year-old
man were obtained via a commercial source (HepAlert) and
cultured in Williams E medium (phenol red free), 1% insulin–
transferrin–sodium selenite, and 1% L-glutamine. Mouse em-
bryonic fibroblasts (MEFs) from wild-type mice or mice with
targeted deletion of RelA (p65), RelB, or dual-specificity
phosphatase 1 (DUSP-1) were generated using previously
characterized mouse models (19–21). Mouse gastrocnemius
muscle tissue was obtained from wild-type C57BL/6 mice (n 
4) immediately postmortem. The tissue was incubated in
DMEM with 10% FBS, 1% L-glutamine, and 4.5 gm/liter
glucose and used immediately in experiments.
Cells were cultured with proinflammatory cytokines
(TNF/IL-1 [0.1–10 ng/ml]) and GCs (cortisol/dexa-
methasone [DEX] [1–100 nM]) alone or in combination. In
some experiments chemical inhibitors of cell signaling path-
ways were added. Cells were pretreated with inhibitor for 2
hours and then treated with cytokines and GCs for 24 hours.
Inhibitors used included p38 MAPK inhibitors (SB202190
[10 M], SB203580 [15 M], and SB239063 [10 M]), ERK
inhibitor (PD98059 [15 M]), protein kinase C inhibitor
(Go6976 [7.9 nM]), NF-B inhibitors (parthenolide [10 M],
pyrrolidine dithiocarbamate [PDTC] [5 mM], lactacystin
[10 M], and TLCK [20 M]), AP-1 inhibitor (curcumin
[100 nM]), and DUSP/MAPK phosphatase inhibitors (sodium
orthovanadate [10 M] and Ro-31-8220 [10 M]).
All studies were approved by the local research ethics
committee, and all subjects provided written informed consent.
All animal experiments and procedures were approved by the
University of Birmingham Animal Care and Use Committees.
RNA extraction and reverse transcription (RT). RNA
was extracted from cultured fibroblasts using the single-step
extraction method (TRI Reagent). Aliquots (1 g) of RNA
were then reverse transcribed using random hexamers (Pro-
mega).
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RNA ligase–mediated rapid amplification of comple-
mentary DNA (cDNA) ends (RLM-RACE) analysis of 11-
HSD1 messenger RNA (mRNA) transcripts. Total RNA was
isolated from MG-63 cells and synovial fibroblasts (from
patients with either OA or RA) that were left untreated or
treated with 10 ng/ml IL-1, 100 nmoles/liter DEX, or a
combination of IL-1 and DEX. DNA was removed using a
Turbo DNA-free kit according to the instructions of the
manufacturer (Ambion). RLM-RACE was carried out using a
GeneRacer kit as recommended by the manufacturer (Invit-
rogen).
For amplification of the 5 end of the cDNA, the
11-HSD1 gene–specific primer (5-GGGCAACAAA-
TTGCTCTGCGAAGGT-3) and the GeneRacer 5 primer
supplied with the kit were used. After gel purification, PCR
products were cloned into pGEM-T Easy vector (Promega)
and sequenced.
Assays for 11-HSD1 mRNA stability. The stability of
11-HSD1 mRNA relative to 18S ribosomal RNA (rRNA) was
determined using real-time RT–polymerase chain reaction
(PCR). MG-63 cells were treated for 4 hours with 10 ng/ml
IL-1, 100 nM DEX, or a combination of IL-1 and DEX.
Cells were then treated with 1 g/ml actinomycin D to arrest
gene transcription. The change in 11-HSD1 mRNA expres-
sion relative to 18S rRNA was measured after a further 4 hours
and 20 hours, and results were used to derive the Ct value.
Real-time PCR. Expression of mRNA was assessed by
real-time PCR with an ABI 7500 system (Applied Biosytems)
using a previously reported technique (13). Reaction condi-
tions were as follows: 50°C for 2 minutes, 95°C for 10 minutes,
and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
Data were obtained as Ct values (the cycle number at which
logarithmic PCR plots cross a calculated threshold line) and
used to determine Ct values (Ct of target gene  Ct of
housekeeping gene) as raw data for gene expression (high
Ct  low gene expression). The fold change in gene expres-
sion was determined by subtracting Ct values of treated cells
from the values obtained with their respective control samples.
The resulting Ct values were then used to calculate fold
change in gene expression according to the equation 2ACt.
Enzyme assays for 11-HSD. Confluent cell monolay-
ers and tissue explants were assayed using a thin-layer
chromatography–based system as previously reported (22).
Cortisone along with tracer amounts of 3H-cortisone (gener-
ated in-house as previously described [22]) was added, and
tissue was incubated at 37oC for various time intervals (2–24
hours) to optimize measurement of cell or tissue activity.
Examination of 11-HSD1 gene reporter activity using
dual-luciferase reporter assays. Previously described con-
structs containing 11-HSD1 promoter sequences immediately
5 to the classic exon 1 of the human HSD11B1 gene (23) were
subcloned into pGL3-Enhancer Vector (Promega) in order to
examine the effect of IL-1 or GCs on 11-HSD1 promoter
activity. MG-63 cells were transiently transfected with the
promoter constructs using Lipofectamine Plus according to the
recommendations of the manufacturer (Invitrogen). Cells were
grown to 50–60% confluence in 24-well plates before transfec-
tion with 0.8 g DNA, 8 l PLUS reagent, 8 l phRL-TK
Renilla luciferase vector (0.02 g; Promega), and 2 l Lipo-
fectamine reagent made up to a final volume of 250 l with
serum free medium. After treatments were added, cells were
incubated for a further 48 hours. All transfections were
performed in triplicate. Control wells contained cells in serum-
free medium. After incubation for 3 hours, 1 ml of growth
medium containing FBS was added per well. Cells were treated
and incubated for 48 hours.
Transfected cells were washed in phosphate buffered
saline and lysed in 100 l 1 passive lysis buffer (Promega). A
Dual-Luciferase Reporter Assay System (Promega) was used
to measure the promoter activity of each construct (in relative
light units, corrected for transfection efficiency).
RelA nuclear translocation assays. The translocation
of RelA (p65) from cytoplasm to nucleus was examined in
primary synovial fibroblasts that were left untreated or treated
with TNF or with a combination of TNF and DEX, with or
without NF-B inhibitors (parthenolide and PDTC). Cells
were pretreated for 2–17 hours before nuclear isolation. RelA
protein content within the nucleus was determined by enzyme-
linked immunosorbent assay using a TransAM NF-B tran-
scription factor assay kit (Active Motif).
Statistical analysis. The normality of data distribution
was examined using the Kolmogorov-Smirnov and Shapiro-
Wilk tests. Data are reported as the mean  SD of replicate
mean values. One-way analysis of variance and Student’s t-tests
were performed using SPSS Data Editor.
RESULTS
Proinflammatory cytokine induction of 11-
HSD1 does not require new protein synthesis. Primary
synovial fibroblasts from RA patients were treated with
TNF and/or DEX, in the presence or absence of
cycloheximide. Analysis of the induction of 11-HSD1
demonstrated that the increase in 11-HSD1 expression
did not depend on new protein synthesis (Figure 1A). In
contrast, the synergistic increase in 11-HSD1 expres-
sion with combined TNF and GCs was partially inhib-
ited by cycloheximide. This indicated that the augment-
ing effect of GCs on TNF-induced 11-HSD1
expression is mediated by a mechanism distinct from
that of TNF alone, which is dependent on new protein
synthesis. Similar results were obtained in MG-63 cells
and C2C12 myoblasts (data not shown).
Regulation of 11-HSD1 expression involves the
classic gene promoter as demonstrated by 5-RACE
analysis. We examined whether differences in expres-
sion of 11-HSD1 with proinflammatory cytokine
and/or GC treatment could arise from differences in
promoter usage. Using primary human synovial fibro-
blasts from patients with RA or OA and MG-63 cells,
5-RACE analysis of mRNA transcripts demonstrated
minor variations in the 5 end of the mRNA transcript,
but all transcripts originated from usage of the conven-
tional proximal promoter (Figure 1B and data not
shown). Furthermore, there was no difference in the
origin or length of the transcripts with IL-1 or DEX
2406 AHASAN ET AL
treatment. Additionally, there was no difference in
transcript length or origin between synovial fibroblasts
obtained from patients with RA and those from patients
with OA (data not shown).
Possible mechanisms for the regulation of 11-
HSD1 mRNA expression with combination GC plus
IL-1 treatment were explored. In MG-63 cells, GCs did
not affect the half-life of 11-HSD1 mRNA expression
in the presence of actinomycin D (an inhibitor of mRNA
transcription), as measured by real-time PCR (half-life
12.5 hours with IL-1 and 13 hours with IL-1 plus
DEX; P not significant) (data available from the corre-
sponding author upon request).
Regulation of 11-HSD1 expression with proin-
flammatory cytokines occurs via the proximal promoter
of HSD11B1. To determine whether induction of 11-
HSD1 expression by proinflammatory cytokines and/or
GCs was due to activation of specific regions of the gene
promoter for this enzyme, promoter-reporter assays
were carried out in MG-63 cells, using dual-luciferase
reporter constructs containing different fragments of the
HSD11B1 proximal gene promoter (Figure 1C). Treat-
ment with IL-1 increased promoter activity of the
1.4-kb sequence upstream of the HSD11B1 gene, in a
dose-dependent manner. Analysis using previously pub-
lished constructs of various lengths (23) demonstrated
Figure 1. Proinflammatory cytokine and glucocorticoid regulation of 11-hydroxysteroid dehydrogenase type 1 (11-HSD1) expression at the
promoter level. A, Effect of the protein synthesis inhibitor cycloheximide (CHX) on HSD11B1 gene transcription in rheumatoid arthritis (RA)
synovial fibroblasts. CHX did not affect induction of 11-HSD1 expression by tumor necrosis factor  (TNF), but partially reduced the additional
expression obtained with TNF and dexamethasone (DEX) combined. Con  control. B, Rapid amplification of complementary DNA ends
(RACE) analysis. Experiments were performed using RA synovial fibroblasts, osteoarthritis (OA) synovial fibroblasts, and MG-63 osteoblasts. Data
shown are for RA synovial fibroblasts; similar results were obtained with OA synovial fibroblasts and MG-63 osteoblasts (data not shown). RACE
analysis demonstrated that RA and OA synovial fibroblasts and MG-63 osteoblasts use the proximal promoter, and there is no difference in
transcription start site according to treatment or disease state. Arrows indicate the transcriptional start site for each transcript. C, Results of
dual-luciferase activity assays in MG-63 cells. Interleukin-1 (IL-1) stimulated proximal promoter activity, but no effect was seen with DEX alone.
The combination of IL-1 and DEX also stimulated promoter activity, but not to a greater extent than that obtained with IL-1 alone. P values are
versus control. Values in A and C are the mean  SD.
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that IL-1 treatment stimulated promoter activity with
all fragments greater than 300 bp in length, but this
was not observed with the 262-bp construct (Figure 1C).
Additional reporter activity was found in the 800-bp
fragment, compared to the 1.4-kb sequence. This indi-
cated that the IL-1 signal is mediated through several
distinct regions of the proximal promoter. Importantly,
in contrast to the findings with regard to mRNA expres-
sion and enzyme activity, DEX treatment did not induce
reporter activity, and treatment with DEX and IL-1 in
combination led to reduced gene reporter activity com-
pared to that observed with IL-1 alone. This demon-
strated an inhibitory effect of DEX on induction of
11-HSD1 expression by IL-1 in this region of the
promoter.
Suppression of 11-HSD1 expression by chemi-
cal inhibitors of NF-B signaling. The underlying mech-
anism for regulation of 11-HSD1 expression was exam-
ined initially in myocytes, using a range of chemical
inhibitors with selectivity for various signaling pathways.
Inhibitors of AP-1, ERK, and protein kinase C signaling
had no effect on either basal expression of 11-HSD1 or
induction of expression of the enzyme in response to
proinflammatory cytokines or GCs (data not shown). In
contrast, a range of inhibitors of NF-B signaling had a
significant inhibitory effect on basal 11-HSD1 mRNA
expression and enzyme activity in C2C12 myoblasts
(Figure 2A). In a model of differentiation from a
pluripotential mesenchymal cell toward myotubes,
NF-B inhibition (using parthenolide plus PDTC) was
effective in inhibiting 11-HSD1 activity at all stages of
differentiation (Figure 2B). This inhibition was rapidly
reversible upon withdrawal of the inhibitor (data avail-
able from the corresponding author upon request).
To ensure that NF-B activity was the prime
regulator of 11-HSD1 activity in musculoskeletal tissue
ex vivo as well as in vitro, we examined the effect of
NF-B inhibition on mouse muscle tissue collected
immediately postmortem (Figures 2C and D). Expres-
sion of 11-HSD1 in this tissue was stable over 18 hours
of incubation. Inhibition of NF-B using parthenolide
plus PDTC resulted in a rapid and substantial decrease
in 11-HSD1 mRNA expression and enzyme activity in
this tissue.
Figure 2. Effect of NF-B inhibitors on 11-hydroxysteroid dehydrogenase type 1 (11-HSD1) oxoreductase expression and activity in C2C12
myoblasts. The inhibitors used were parthenolide (Parth) (10 M), pyrrolidine dithiocarbamate (PDTC) (5 mM), and lactacystin (Lacta) (10 M).
A and B, Effects of NF-B inhibition on basal expression and activity of 11-HSD1 (A) and on the increase seen during myoblast differentiation (B).
C and D, Effects of NF-B inhibition on 11-HSD1 expression (C) and activity (D) in freshly isolated muscle tissue from 4 mice. Values are the
mean  SD. P values in A, C, and D are versus control.
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Suppression of cytokine-induced 11-HSD1 ex-
pression by chemical inhibitors of the NF-B pathway.
The effect of NF-B inhibitors on the increased expres-
sion of 11-HSD1 following treatment with proinflam-
matory cytokines and/or GCs was examined in a range of
cells arising from the mesenchymal stromal cell lineage
(Figure 3). NF-B inhibition using parthenolide and
PDTC was highly effective in attenuating 11-HSD1
activity induced by TNF or by combined TNF and
GC. To ensure that the responses observed in synovial
fibroblasts were representative of changes in normal
synovial fibroblasts, synovial fibroblasts were obtained
from healthy donors. Responses obtained using synovial
fibroblasts from patients with RA were similar to those
of normal fibroblasts (data not shown). In contrast,
11-HSD1 activity in primary human hepatocytes was
not responsive to proinflammatory cytokines and was
not affected by NF-B inhibition (data available from
the corresponding author upon request).
The increase in 11-HSD1 expression with pro-
inflammatory cytokines is mediated through RelA (p65)
activity. To further define the specific components of
NF-B signaling that regulate 11-HSD1 expression, we
examined the effect of targeted deletion of components
of both the classic and the alternate NF-B signaling
cascade. Deletion of RelB in MEFs had no impact on
the levels of 11-HSD1 observed after treatment with
proinflammatory cytokine or GC (Figure 4A). In con-
trast, RelA deletion entirely prevented the induction of
11-HSD1 in response to TNF or IL-1 (Figure 4A
shows mRNA expression data; these changes were par-
alleled by changes in enzyme activity [data not shown]).
These results indicate that the classic NF-B pathway
has a central role in mediating cytokine induction of
11-HSD1.
Glucocorticoids do not prevent TNF-induced
translocation of RelA to the nucleus. GCs have been
reported to have a significant inhibitory effect on pro-
inflammatory cytokine–induced nuclear translocation of
NF-B in some cells and tissues (24–26). We therefore
examined the effect of GC treatment on cytokine-
induced translocation of RelA from cytoplasm to nu-
cleus in synovial fibroblasts obtained from RA patients.
Treatment with TNF increased the level of RelA
protein in the nucleus (Figure 4B). This effect was
efficiently blocked by an NF-B inhibitor. In contrast,
Figure 3. NF-B is the major mediator of the induction of 11-HSD1 by TNF in fibroblasts (normal synovial and dermal; n  3 independent
patient lines), osteoblasts, and myoblasts. The effect of NF-B inhibition (INH) with parthenolide (10 M) plus pyrrolidine dithiocarbamate (5 mM)
on the induction of 11-HSD1 activity by TNF, DEX, and their combination is shown. Values are the mean  SD. See Figure 1 for other
definitions.
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GCs had no impact on TNF-stimulated RelA translo-
cation, indicating failure to inhibit NF-B activity at the
level of nuclear translocation.
The p38 MAPK pathway also regulates the effect
of proinflammatory cytokines on 11-HSD1 expression.
Proinflammatory cytokines are powerful stimulators,
and GCs powerful inhibitors, of the p38 MAPK pathway
in stromal cells. We therefore examined whether p38
MAPK signaling was involved in the regulation of
11-HSD1 activity in response to proinflammatory cy-
tokines or GCs. We found that selective inhibitors of p38
MAPK signaling augmented TNF stimulation of 11-
HSD1 expression, but had no effect on basal expression
(Figure 5A). The increase in 11-HSD1 expression over
that obtained with TNF treatment alone was equiva-
lent when TNF was combined with p38 MAPK inhib-
itor or with DEX. Furthermore, the level of 11-HSD1
expression after treatment with a combination of TNF,
DEX, and p38 MAPK inhibitor was not significantly
different from that observed after treatment with TNF
and DEX without p38 MAPK inhibitor or TNF and
p38 MAPK inhibitor without DEX (Figure 5A). These
data indicate that GCs augment cytokine induction of
11-HSD1 expression via their ability to inhibit p38
MAPK.
GCs increase the effect of proinflammatory cyto-
kines on 11-HSD1 expression indirectly through in-
duction of DUSP-1 activity. The finding that the effect
of GCs on cytokine-induced expression of 11-HSD1 is
dependent on new protein synthesis (Figure 1A) indi-
cates that this particular effect of GCs is mediated in an
indirect manner. In osteoblasts and fibroblasts, GCs
primarily inhibit p38 MAPK activity through the induc-
tion of DUSP-1 expression and activity (27,28). Nonspe-
cific chemical inhibitors of DUSP-1 (e.g., sodium or-
thovanadate; Ro-31-8220) had no effect on TNF/IL1
induction of 11-HSD1 in MG-63 cells, but prevented
the augmentation of cytokine-induced 11-HSD1 ex-
pression with GCs (data available from the correspond-
ing author upon request). The specific role of DUSP-1
Figure 5. Molecular analysis of the role of p38 MAPK signaling in
11-HSD1 expression. A, Effect of the p38 MAPK inhibitor SB202190
on the induction of 11-HSD1. Expression of 11-HSD1 expression
with TNF plus SB202190 treatment was increased to a similar extent
as was observed with TNF plus DEX treatment. B, Effect of
dual-specificity phosphatase 1 (DUSP-1) deletion in mouse embryonic
fibroblasts (lines from 4 embryos). The results indicate that inhibition
of p38 MAPK by DEX occurs primarily through induction of DUSP-1.
Values are the mean  SD. NS  not significant; WT  wild-type;
KO  knockout (see Figure 1 for other definitions).
Figure 4. Molecular analysis of the role of NF-B in regulation of
11-HSD1 expression. A, Effect of treatments (TNF, IL-1, DEX,
combined TNF and DEX, or combined IL-1 and DEX) on 11-
HSD1 mRNA expression in mouse embryonic fibroblasts from wild-
type (WT), RelB-knockout (KO), and RelA-knockout mice (all on a
C57BL/6 background; lines from 9 embryos). B, Effect of TNF with
or without DEX and with or without NF-B inhibitor (INH) on RelA
nuclear translocation in RA synovial fibroblasts. RelA (p65) translo-
cated to the nucleus in response to TNF treatment. This effect was
not blocked by glucocorticoid, but was completely inhibited by NF-B
inhibitor. Values are the mean  SD. See Figure 1 for other
definitions.
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was confirmed in experiments using MEFs from mice
with transgenic disruption of DUSP-1 (Figure 5B). Basal
and TNF-stimulated levels of 11-HSD1 expression
were the same in DUSP-1–knockout and wild-type
MEFs, but after combined treatment with TNF and
GCs, expression of 11-HSD1 was significantly reduced
in DUSP-1–knockout MEFs.
DISCUSSION
We have previously shown that increased expres-
sion of 11-HSD1 during inflammation is an important
mechanism regulating the immune response (12,13).
This increase in expression is common to cells that arise
from mesenchymal stromal cells, such as fibroblasts,
myoblasts, and osteoblasts (7,8,10,12). Additionally, a
synergistic induction of 11-HSD1 expression by proin-
flammatory cytokines and GCs is seen in these cell types
(13). This synergistic interaction has a significant impact
in reducing the production of IL-6 by synovial fibro-
blasts. In the present study we demonstrated the molec-
ular basis for regulation of 11-HSD1 in these cells. This
regulatory mechanism depends on the relative balance
of NF-B and p38 MAPK signaling pathways (illustrated
schematically in Figure 6) and is distinct from mecha-
nisms that regulate 11-HSD1 activity in other cell types
(such as hepatocytes). This feedforward mechanism
allows for sustained GC production only in the presence
of continuing proinflammatory stimulation.
An unusual finding with regard to the synergistic
induction of 11-HSD1 activity was that GCs aug-
mented proinflammatory signaling, rather than inhibit-
ing it. Our data indicate that this augmentation is due to
inhibition of p38 MAPK activity. Another unusual fea-
ture is the antiinflammatory role of NF-B. NF-B
signaling was previously thought to be exclusively proin-
flammatory, but there are now examples of situations in
which it appears to have an important antiinflammatory
role (29). The involvement of NF-B in the production
of GCs is also interesting, and at first glance unexpected,
since NF-B signaling is a major target of GCs in many
cell types (24). GCs inhibit NF-B signaling in immune
cells and tissues, e.g., T lymphocytes, thymocytes,
splenocytes, and lymph nodes (25,26), but only recently
has it been explored in cells of the mesenchymal stromal
lineage. For example, GCs are unable to repress NF-B
action in osteoblasts (30). Similar findings in synovial
fibroblasts have also been reported (31). Data presented
here suggest that this lack of inhibition of NF-B by GCs
is a critical feature of the regulation of 11-HSD1. This
mechanism of regulation ensures that the production of
GCs within cells derived from mesenchymal precursors
continues to be sustained in the presence of continuing
activation of NF-B signaling, but will decrease rapidly
when this signal is removed.
We have demonstrated earlier that during syno-
vial inflammation, the level of active GCs within the
joint increases (8). This appears to be a consequence of
increased expression of 11-HSD1 within synovial fibro-
blasts, and is likely to be an adaptive response to reduce
joint inflammation. In many situations it is likely that the
increase in GCs will facilitate resolution of the inflam-
mation. The increased expression of 11-HSD1 within
synovial tissue will also amplify the effect of therapeutic
GCs since the enzyme also converts inactive prednisone
to active prednisolone (32). This will result in the
preferential accumulation of active prednisolone within
the synovium. However, with chronic inflammation the
high levels of GCs within the tissue could adversely
affect adjacent bone tissue and undermine the integrity
of the joint. Similar considerations apply to inflamed
muscle tissue, where short-term increases in GC levels
are likely to have a beneficial antiinflammatory effect
whereas chronic excess of GC is known to induce muscle
atrophy.
The identification of a distinct pathway regulat-
ing 11-HSD1 activity in osteoblasts, synovial fibro-
blasts, and myoblasts creates new opportunities for
therapeutic regulation of 11-HSD1 activity in these
tissues. Therapeutic modulation could be achieved
though targeting of either the p38 MAPK or the NF-B
pathway. The demonstration that p38 MAPK inhibitors
can increase 11-HSD1 expression selectively in cells
Figure 6. Schematic representation of the pathways by which TNF/
IL-1 and glucocorticoids regulate 11-HSD1 expression and activity
in musculoskeletal cells. TNF/IL-1 exert both stimulatory and
inhibitory effects via NF-B and p38 MAPK pathways, respectively.
The inhibitory pathway can be blocked by glucocorticoids, primarily
through a dual-specificity phosphatase 1 (DUSP-1)–dependent mech-
anism. See Figure 1 for other definitions.
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exposed to proinflammatory cytokines suggests that
similar drugs could be used to increase GC levels in a
tissue- and inflammation-specific manner. The efficacy
of p38 MAPK inhibitors in reducing joint inflammation
has been demonstrated in experimental models of in-
flammatory arthritis (33), and it is possible that the
mechanism described herein could contribute to this
efficacy.
In contrast to strategies designed to increase
11-HSD1 activity, pharmaceutical companies have fo-
cused on developing inhibitors of this enzyme, primarily
for use in metabolic disorders associated with GC excess
(34). Systemic inhibitors of the 11-HSD1 enzyme itself
are becoming available, but their use in inflammatory
states could be complicated by the reported expression
of 11-HSD1 in immune tissue (5,35). There is a possi-
bility that inhibition of 11-HSD1 within immune tissue
could lead to an exaggerated immune response. Further-
more, 11-HSD1 activity in the liver is believed to
contribute significantly to total-body GC metabolism
and its inhibition could have a detrimental impact on the
circulating level of GCs, again leading to an increase in
the proinflammatory aspects of the immune response.
Characterization of the NF-B pathway as an important
regulator of GC synthesis in mesenchymal stromal cells
suggests that NF-B inhibitors could usefully inhibit GC
synthesis at sites such as muscle and bone. Rather than
promoting an inflammatory response through effects on
11-HSD1 inhibition in immune cells at sites of chronic
inflammation, it is more likely that NF-B inhibitors
would have an antiinflammatory effect, given their
widely acknowledged antiinflammatory action on im-
mune cells of hematopoietic origin. Further work should
clarify the actual role of targeted inhibition of 11-
HSD1 activity in these situations.
In the present report we describe the molecular
regulation of 11-HSD1 activity in mesenchymal stro-
mal cells. The involvement of two major pathways,
normally considered proinflammatory, to reciprocally
regulate expression of an antiinflammatory gene sug-
gests that these mechanisms are of fundamental impor-
tance in the tissue response to inflammation.
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